Compass Therapeutics (NASDAQ:CMPX) Sees Large Volume Increase - Should You Buy?

Key Points

• Compass Therapeutics shares experienced a significant trading volume increase of 297% on Wednesday, with approximately 5.7 million shares traded compared to 1.4 million shares in the previous session.
• Several analysts have issued ratings for Compass Therapeutics, with prices ranging from $9.00 to $32.00, indicating a generally positive outlook and a consensus price target of $13.10.
• Institutional investors hold 68.43% of the company's stock, with significant new stakes purchased recently by various funds, reflecting increased interest in the company.

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) shares saw unusually-high trading volume on Wednesday . Approximately 5,733,165 shares traded hands during mid-day trading, an increase of 297% from the previous session's volume of 1,445,506 shares.The stock last traded at $4.20 and had previously closed at $4.10.

Wall Street Analysts Forecast Growth

CMPX has been the subject of a number of analyst reports. Lifesci Capital initiated coverage on Compass Therapeutics in a report on Monday, October 6th. They issued an "outperform" rating and a $10.00 price target for the company. Raymond James Financial upgraded Compass Therapeutics to an "outperform" rating and set a $9.00 target price for the company in a research note on Tuesday, July 1st. D. Boral Capital reiterated a "buy" rating and issued a $32.00 target price on shares of Compass Therapeutics in a research note on Tuesday, August 12th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Compass Therapeutics in a research note on Wednesday, October 8th. Finally, Guggenheim upped their target price on Compass Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a research note on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Compass Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $13.10.

Compass Therapeutics Price Performance

The stock has a 50-day simple moving average of $3.55 and a 200-day simple moving average of $2.77. The stock has a market cap of $575.24 million, a PE ratio of -9.24 and a beta of 1.48.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). As a group, equities research analysts anticipate that Compass Therapeutics, Inc. will post -0.36 EPS for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Vontobel Holding Ltd. purchased a new stake in shares of Compass Therapeutics in the first quarter worth about $57,000. American Century Companies Inc. purchased a new stake in shares of Compass Therapeutics in the first quarter worth about $140,000. Wellington Management Group LLP purchased a new stake in shares of Compass Therapeutics in the first quarter worth about $423,000. Charles Schwab Investment Management Inc. boosted its position in shares of Compass Therapeutics by 4.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 297,880 shares of the company's stock worth $566,000 after buying an additional 11,689 shares during the period. Finally, Nuveen LLC purchased a new stake in shares of Compass Therapeutics in the first quarter worth about $579,000. Hedge funds and other institutional investors own 68.43% of the company's stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.